At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase II Trial of Sipuleucel T Immunotherapy Preceded by Sensitizing Radiation Therapy and Sipuleucel-T Alone in Patients With Castrate Resistant Metastatic Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating sipuleucel-T, external beam radiation therapy, and 1 other intervention for Adenocarcinoma of the Prostate and 5 related conditions. Completed, enrolled 51 participants across 3 sites.
Detailed Summary
This randomized phase II trial studies how well giving sipuleucel-T with or without radiation therapy works in treating patients with hormone-resistant metastatic prostate cancer. Vaccines may help the body build an effective immune response to kill tumor cells. Radiation therapy uses high energy x rays to kill tumor cells. It is not yet known whether giving sipuleucel-T vaccine is more effective with or without radiation therapy in treating prostate cancer
Study Details
Timeline
Interventions
Given IV
Undergo external beam radiation therapy
Correlative studies